Overview

A Phase I Study of RC88-ADC in Subjects With Advanced Malignant Solid Tumors

Status:
Recruiting
Trial end date:
2022-05-31
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety, pharmacokinetics and effect of RC88-ADC for injeciton in subjects with advanced malignant solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
RemeGen
RemeGen Co., Ltd.